Publications by authors named "Angela Dymond"

Claim this Profile
O
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.
Myung-Ju Ahn, Byoung Chul Cho, Xiaoling Ou, Andrew Walding, Angela W Dymond

J Thorac Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The functional observational battery and modified Irwin test as global neurobehavioral assessments in the rat: Pharmacological validation data and a comparison of methods.
William S Redfern, Angela Dymond, Isobel Strang, Sharon Storey, Claire Grant

J Pharmacol Toxicol Methods· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Helen Tomkinson, Eileen McBride, Paul Martin, Eleanor Lisbon, Angela W Dymond

Clin Ther· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau, Fiona Blackhall, Noor Md Haris, Angela W Dymond

Br J Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis.
Angela W Dymond, Cathy Elks, Paul Martin, David J Carlile, Gabriella Mariani

Eur J Clin Pharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
Angela W Dymond, Paul Martin, Karen So, Yifan Huang, Paul Severin

J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Angela W Dymond, Karen So, Paul Martin, Yifan Huang, Paul Severin

Eur J Clin Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Diansong Zhou, Karen So, Angela W Dymond, Torbjorn Vik, Nidal Al-Huniti

Clin Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.
Angela W Dymond, Colin Howes, Christine Pattison, Karen So, Gabriella Mariani

Clin Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis